It has been just over a year since Ozurdex, a dexamethasone-sustained release implant, was first funded by Pharmac for diabetic macular oedema (DMO), the most common cause of visual loss in our working-age population.
Premium subscriber content
Sign in if you have a Digital or Print + Digital subscription. Don’t have one yet? Digital subscribers get full access to this article from $40/year +GST.
- Premium exclusive content
- Full digital magazine archive
- Early access to new articles
- 11 print magazine issues per year
